Incyte Genomics - hat die noch wer? - 500 Beiträge pro Seite

[catmat]

Guten Tag,
wie ist Eure Meinung, im Vergleich zu anderen Titeln hinkt sie ja noch gewaltig hinterher.
Soll man raus?

[moz01]

Ich denke du solltest die Position behalten und ev. aufbauen.

Da dieser Wert auch wie andere z.B.: Myriad, Visible Genetics, Molecular Devices Corp. vom Bioinformatik-Boom profitieren werden.

mfg moz01

[lupo1]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[pollyanna]

Incyte profitiert momentan enorm vom Bioinformatik-Boom und bleibt daher kurzfristig haltenswert.
Als Anwender der Incyte-Produkte bin ich allerdings überhaupt nicht zufrieden. Aus zuverlässiger Quelle weiß ich auch das ein schweizer Pharmamulti ab Anfang 2001 seinen Kooperationsvertrag mit Incyte aufkündigt.
Wenn diese Meldung raus kommt könnte das den Kurs drücken.

[fenstergriff]

Aufwärts geht´s

fenstergriff

[GMBH]

@ pollyanna

Also wir sind hochzufrieden mit den Produkt Incyte und wollen als schweizer Großkonzern ab 2001 unsere Zusammenarbeit mit Incyte sogar ausbauen.

Mir ist nicht klar, welcher größerer schweizer Großkonzern von Incyte abspringen sollte.

Also, Gerüchte, Gerüchte, Gerüchte...

[claudiusz]

ich halte Incyte seit 14 Monaten...
Wechselbad der Gefühle, aber die Firma überzeugt mich .

Claudio

[4runner]

Meine Meinung: Es gibt wesentlich schlimmere Kursschwankungen. Außerdem ist INCYTE ein solides Unternehmen. Erstens sind die nicht von irgend einem schweizer Unternehmen abhängig und zweitens wird der kurz sowieso erst in einigen Jahren so richtig interessant. Ich bin seit 6 Monaten dabei und werde nicht so schnell verkaufen.

[Kelbi]

Man kann mit Incyte ganz gut traden(siehe Chart) aber ansonsten denke ich Anlagehorizont mindestes 3 Jahre, aber dann nach oben...viel möglich.

[ähhhh]

Hallo, ich habe von meiner Bank die Mitteilung erhalten, dass ich meine Aktien zu einem Stückpreis von 26,00 USD an die Gesellschaft Corporate Investsm. verkaufen kann. (Übernahmeangebot)
Jetzt hab ich mal eine Frage, wer ist den so blöd und verkauft seine Incyte Aktien zu einem Stückpreis von 26 USD wenn die Aktien in Deutschland 44 Euro Wert sind?????
Auf eine logische Begründung bin ich nun mal gespannt!
Gruß Jens

[IWA Japan]

es gibt keine logische Erklärung.

du hast vielmehr ein Abzocker Angebot einer unseriösen Firma erhalten.

Deine Bank ist jedoch verpflichtet, dieses ungeprüft an dich weiterzuleiten.

Fazit: so einem Müll niemals zustimmen

[fritzchenI]

Hi wie gehts weiter mit incyte, will evtl. einsteigen
muß dafür aber in kontron, plambeck Unternehmen mit schwarzen zahlen
aussteigen, ist es zu früh
würde mich über eure meinung freuen

[mainectar]

soll man jetzt einsteigen?????????

[V.Mac]

logo, immer druff !
Habe auch vor rund drei Monaten, leider noch etwas zu früh, bei 52,50 (splittbereinigt) gekauft und warte nun, daß der Kurs mal wieder in diese Regionen vorstößt.

Bis dahin bin ich allerdings bei Kursen um 32- 35 Euro bereit, noch mal ein wenig nachzulegen.

V.Mac

[Andalus]

Bin heute - bei 28 USD oder 33 Euro mal wieder eingestiegen!
Schau`n mer mal

[pinklady]

Wie geht es weiter mit Incyte?
Keine neuen News zu dieser Aktie?
Sind sie auf diesem Niveau ein Kauf?Die anderen Biotechs steigen nur incyte nicht. Warum?

[kpdoerle]

wie geht es weiter,
habe das letzte mail incyte zu 39e gekauft.
seitdem war die Entwicklung nicht gerade berauschend.
bin am überlegen, ob ich nochmal nachkaufen soll (unter 30e)

[kpdoerle]

Friday December 29, 8:30 am Eastern Time

Press Release

SOURCE: Incyte Genomics, Inc.

Incyte Completes Acquisition of Proteome, Inc.

PALO ALTO, Calif., Dec. 29 /PRNewswire/ -- Incyte Genomics, Inc.
(Nasdaq: INCY - news), today announced the completion of its
acquisition of Proteome, Inc., a privately held company based in
Beverly, Massachusetts. As a part of the transaction, which was
announced on December 21, 2000, Incyte will pay $77 million in
a combination of cash and equity in exchange for all of Proteome`s
outstanding capital stock. The transaction will be accounted for as
a purchase.

Incyte Genomics, Inc. is the leading provider of an integrated
platform of genomic technologies designed to aid in the understanding
of the molecular basis of disease. Incyte develops and markets genomic
databases and partnership programs, genomic data management
software, microarray-based gene expression services, related reagents
and services. These products, programs and services assist
pharmaceutical and biotechnology researchers with all phases of drug
discovery and development including gene discovery, understanding
disease pathways, identifying new disease targets and the discovery
and correlation of gene sequence variation to disease. For more
information, visit Incyte`s web site at http://www.incyte.com .

Except for the historical information contained herein, the matters
set forth in this press release, are forward-looking statements within
the meaning of the ``safe harbor`` provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
subject to risks and uncertainties that may cause actual results to differ
materially. For a discussion of factors that may cause results to differ,
see Incyte`s SEC reports, including its Quarterly
Report on Form 10-Q for the quarter ended September 30, 2000.
Incyte disclaims any intent or obligation to update these forward-looking
statements.

SOURCE: Incyte Genomics, Inc.

[eser]

Hallo Leute

Kursziel innerhalb zwei woche 45 EUR

[maxmara]

@eser

Woher hast du dieses Kursziel?
Von den Sternen?????

[Beamen]

eser. damit hast du dich hiermit selbst qualifiziert.
grossartig leistung.
Mein Gott, wenn Hoffnung Kursziele definiert...

Meiner Meinung sieht es derzeit so aus, als wuerden
wir zurueck auf ca. 20$ fallen, um (und das ist MEINE
Hoffnung) eine Doppeltief auszubilden, von wo aus wir
dann gesund steigen koennen.

[V.Mac]

Langsam wirds mal Zeit, daß hier ne positive Meldung kommt !

Die Baisse ist mir persönlich jetzt genug !

V.Mac

[V.Mac]

da ich im März/April leider den Mut nicht hatte, um nachzufassen, habe ich es heute zu glatt 20 € getan.

Vor drei Monaten hätte man sie noch um 12 -13 € bekommen. Und mittlerweile ist sie bereits bis über 25 € gegangen um jetzt noch mal zu sinken. Ich hoffe, nicht mehr tiefer.

Auf jeden Fall sollte die Talsole erreicht sein mit den Lows im März/April.

Ich werde mal in den nächsten Tagen noch ein wenig rumstöbern im Netz der Netze und Artikel suchen.

V.Mac

[V.Mac]

bisher hab ich noch nicht viel Zeit in die INCY investiert.

Kommt aber noch, spätestens wenn mal wieder Zahlen anstehen.

Muss mal weiter sehen.

V.Mac

[V.Mac]

Die Zahlen müssten so um Mitte Oktober kommen, die letzten kamen jedenfalls am 19.7.01

Hoffentlich gehts bis dahin noch mal schön runter auf 12 € und danach dann langsam und stetig auf 35 €.

V.Mac

[V.Mac]

Zahlen::

Der Kurs hat sich seit letztem Mal nicht viel bewegt, aber es gibt heute Zahlen. Obwohl es ziemlich viel Text ist, lohnt sich imho das Lesen.


Incyte Genomics Reports Record Revenues for Third Quarter 2001
THURSDAY, OCTOBER 25, 2001 8:30 AM
- PRNewswire

Announces Restructuring to Focus on Its Core Information Business and Leverage Its Industry-Leading Intellectual Property Portfolio in Licensing And Therapeutic Discovery While Improving Overall Operating Performance

PALO ALTO, Calif., Oct 25, 2001 /PRNewswire via COMTEX/ -- Incyte Genomics, Inc. , the leading genomic information company, today reported consolidated financial results for the three and nine months ended September 30, 2001. Incyte also announced a restructuring that includes plans to exit certain unprofitable custom genomics operations and reductions in its staff to focus on core operations.

Revenues for the quarter increased 10% to $57.3 million from $52.0 million for the comparable quarter in 2000. This brought the revenues for the nine-month period ending September 30, 2001 to $164.5 million, a 19% increase over revenues of $138.8 million for the same nine-month period in 2000.

"Consistent with our strategy to focus on the increasing value of our unique combination of intellectual property and genomic information content, we announced some exciting collaborations during this quarter that include the antibody licensing deal with Genentech, the therapeutic antibody validation efforts with Medarex and several other licensing and subscription transactions," said Roy A. Whitfield, Chief Executive Officer of Incyte. "The various collaborations demonstrate an increasing demand for our intellectual property and content while building our internal therapeutic discovery programs."

Third-quarter revenues from Database and Partnership programs increased 13% to $45.2 million from $39.8 million for the same quarter in 2000. Third-quarter revenues for Custom Genomics programs were $12.2 million, consistent with the revenue level for the same quarter in 2000.

Incyte reported a net loss for the quarter of $17.8 million, or $0.27 per diluted share, compared with a net loss of $7.6 million, or $0.12 per diluted share, for the same quarter in 2000. Non-cash charges associated with goodwill amortization accounted for $3.0 million of the 2001 net loss. Also included in the results for the third quarter of 2001 were:


"Although the total loss for the quarter was $17.8 million, it included $3.0 million associated with goodwill amortization, $5.8 million from the loss related to the divestiture of the transgenics operations, $5.3 million from the write down of our long term investments and $1.1 million resulting from the adoption of SFAS 133," said John Vuko, Chief Financial Officer of Incyte. "Excluding these items, the net loss for the quarter was $2.6 million. This demonstrates the strength of the core database and partnership business considering that it is supporting the ongoing investment in our internal therapeutic discovery and full-length gene programs."

"We remain very pleased with the strength of our core database and partnership businesses. Our recent results continue to validate the great value in Incyte`s areas of key competitive advantage, which include information and intellectual property rights relating to genes, proteins and antibodies," said Mr. Whitfield. "However, as we have indicated in the last two earnings conference calls, the markets for microarrays, public domain clones, transgenics and contract-sequencing services, where success is less dependent on our key competitive advantages, have been marked by increasing competition and margin erosion that appear to be a permanent trend. As a result, the custom genomics operations no longer provide a strategic benefit to our core database and intellectual property business and have increasingly been diluting our focus and our resources while contributing to our operating losses. Thus, we made the hard decision to divest or restructure these non-core product lines to enable us to more fully capitalize on the opportunities available to our core businesses."

"Following the restructure, we will continue to participate in the proprietary clone market," said Mr. Whitfield. "With respect to the microarray market, we expect to benefit from the numerous strategic collaborations with microarray manufacturers that rely on our extensive gene content and currently provides a growing royalty stream."

Today, many of the world`s microarray manufacturers have recognized the value of the Incyte LifeSeq Gold gene content and have entered into strategic collaborations with Incyte to standardize their product lines through the inclusion of this information. These collaborations allow Incyte to benefit from the sales of microarrays without having to be a manufacturer of them. The typical microarray collaboration allows Incyte to earn a royalty on each microarray sold. In addition, users of Agilent, Motorola and other microarrays are linked by the Internet back to related Incyte content, creating potential intellectual property licensing opportunities surrounding the genes being analyzed. These strategic benefits are achieved at no cost to Incyte with significant upside revenue potential from royalties and related content and intellectual property licensed over the Internet.

In addition to the discontinuation and restructuring of Incyte`s custom genomics product lines, which will result in the closure of Incyte`s facilities in Fremont, California and St. Louis, Missouri, Incyte also will make infrastructure and other related personnel reductions at its other locations. The company also proposes to discontinue, by year-end, its internal program on therapeutic single nucleotide polymorphisms (SNP) discovery, which has been concentrated in Cambridge, UK. Although the SNP efforts have been successful at generating the valuable intellectual property to complete Incyte patent filings and support internal target validation programs, Incyte proposes to discontinue the program to permit the company to focus its resources on higher priority programs.

Financial Impact and Q4 2001 Guidance

Incyte will be reducing its worldwide workforce by approximately 400 employees. To recognize the costs associated with these actions, in addition to the charge of $5.8 million recorded in the third quarter associated with the transgenics transaction, the company anticipates recognizing an additional non-recurring charge that could exceed $80 million in the fourth quarter. Approximately 25% of the fourth-quarter costs are anticipated to be cash related and the remainder is primarily associated with the write-off of assets. In addition, revenue guidance for Fourth quarter of Fiscal 2001 will be in the range of $50-55 million and will be predominantly database and partnership revenues. Net loss for the quarter, without accounting for restructuring charges, is anticipated to be in the range of $10-15 million.

Impact of September 11, 2001 Terrorist Events

"The tragic events of September 11 have affected us all. Although our immediate business has not been seriously affected, the business has been impacted in another way," said Mr. Whitfield. "As we have disclosed in past conference calls, we have had an aggressive search underway for a president. Recently, a strong, European based candidate for president, with whom we had negotiated the terms of an employment agreement, was extended an offer. As a result of the September 11 events, the candidate declined the offer for personal and family reasons. Although disappointing, the pool of talent we have had access to has been tremendous and has provided numerous other strong candidates."

Company management will host a conference call on Thursday, October 25, 2001 at 9:30 a.m. PDT to discuss the company`s results. The dial-in number for the conference call in the U.S. will be 877-692-2588 and the International number will be 973-872-3462. A replay of the conference call will be available through October 31, 2001 . The replay dial-in number for U.S. and International callers will be 973-341-3080 and the PIN number access code will be 2914135.

Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, and related reagents. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte`s web site at .

Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the Company`s plans to enhance, and to further capitalize on, its core business through the announced restructuring, the increasing demand for Incyte`s intellectual property and content, the impact of Incyte`s collaborations with other third parties in building the Company`s therapeutic discovery programs, market trends, the benefits to the Company to be derived from its strategic collaborations, including the potential royalty, content and intellectual property licensing opportunities for the Company from its microarray collaborations, the number of job losses to be incurred through the Company`s restructuring, guidance as to the expected non-recurring charge for the fourth quarter of 2001, and the components thereof, and as to revenues and net loss for the fourth quarter of 2001, the Company`s progress in its search for a new president, the ability of Incyte`s products and services to enhance the research efforts of its customers and Incyte`s ability to leverage its intellectual property position to become a leader in therapeutic discoveries, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, including Incyte`s ability to obtain and retain customers, the impact of competition and technological advances, the effectiveness and extent of utilization of databases in pharmaceutical research and development, further changes in the Company`s business plan, finalization of the specific list of assets to be written down, the number of employees entitled to receive retention benefits, and other costs to be recognized in connection with the restructuring, changes in consumer demand for the Company`s products, the success of the Company in negotiating future licensing and collaborative transactions, and Incyte`s ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage and to grow its intellectual property portfolio, see Incyte`s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements.


CONTACT: Paul Chirico, Investor Relations & Corporate Communications of Incyte Genomics, Inc., 650-845-4589.


SOURCE Incyte Genomics, Inc.


V.Mac

[V.Mac]

Da heute fast alle Biotechs stark waren, ist auch die INCY mal wieder mit 2stelligem Plus dabei.

Jetzt muß erst mal die 20 € Marke her und dann ist imho noch Luft bis 35 €.

Ist dann die Marke noch geknackt, kanns nur noch nach oben weitergehen.

Was gibts noch für Meinungen ?

V.Mac

[eser]

Hallo Leute...!!!

Jetz ist der bei der 17,60 EUR

[jeckenstreich]

@all
Ob 16 oder 19 EUR, wenn wir mit Hilfe des Gesamtmarktes erst die 20 von oben sehen, können wir auch auf höhere Kurse hoffen.
Gespanntes Warten auf den entscheidenden Kick.
So long

[V.Mac]

gestern wars so weit. Die 20€ Marke ist durchbrochen.

Warum?

1. Zwei "Neue" mit an Board


9:35am 11/27/01 Incyte`s new CEO, CSO prompt upgrade (INCY) By Tomi Kilgore
Incyte Genomics (INCY) is rallying $1.56, or 9.6 percent, to $17.75. Analyst Rob Olan at J.P. Morgan upgraded the stock to "buy" from "long-term buy," and added it to the firm`s "focus list." The upgrade follows the genomics information company`s announcement late Monday that it had named Dr. Paul Friedman as its chief executive, and Dr. Robert Stein as its chief scientific officer. Friedman was formerly president of Dupont`s (DD) pharmaceuticals research laboratories and Stein was an executive vice president at DuPont Pharmaceuticals. "We believe the new management will be able to credibly move the company`s internal discovery efforts forward, and create a drug pipeline for Incyte," Olan said in a note to clients.

So, und 2.

Durch den Einstieg der beiden Neuen entesteht jetzt eine gewisse Fantasie, daß INCY nicht mehr nur Daten verwaltet sondern selbst in die aktive "drug" - Forschung einsteigen könnte.

Incyte rallies on hopes of drug-development future
TUESDAY, NOVEMBER 27, 2001 1:30 PM
- Reuters U.S. Company News

Incyte rallies on hopes of drug-development future

11/27/2001 1:30:00 PM
By Ransdell Pierson

NEW YORK, Nov 27 (Reuters) - Investors on Tuesday rallied behind shares of Incyte Genomics Inc. (INCY) on expectations its newly picked management team will spur the gene-information firm into the far-more-profitable area of making drugs, analysts said.

Incyte, which develops and markets databases of genetic information and related products for drug firms, said late on Monday that it had named two former senior executives of DuPont Co.`s (DD) pharmaceuticals unit to its own top management posts.

Paul Friedman, president of the DuPont unit until its acquisition by Bristol-Myers Squibb Co. (BMY) in October, was chosen to replace Roy Whitfield as Incyte`s chief executive officer. Whitfield, in turn, was elected chairman of the company`s board of directors, succeeding fellow co-founder Randy Scott.

The Palo Alto, California-based company added it had chosen Robert Stein, a former research chief of the DuPont drug unit, as Incyte`s president and chief scientific officer.

Shares of Incyte were up $2.55, or 15.8 percent, to $18.74, in heavy afternoon trade on the Nasdaq.

"The appointments of Friedman and Stein are the strongest signals to date that Incyte is thinking about developing its own drug-development capabilities," Gruntal & Co. biotech analyst Darren Mac said.

Friedman and Stein worked together for years not only in senior roles at DuPont but earlier for Whitehouse Station, New Jersey-based drug giant Merck and Co. (MRK) At DuPont, they helped develop the firm`s Sustiva treatment for the HIV virus.

Mac speculated that Friedman and Stein will not be able to resist the itch to steer Incyte into drug development -- a trail that is already being blazed by rival gene-database firm Celera Genomics Group (CRA) of Rockville, Maryland.

It would take years for Incyte to develop an in-house pharmaceuticals operation if it chooses to go down that expected path, Mac said. But he said drugmaking makes sense because Incyte`s current focus on selling information about genes and their functions is losing money, with prices for such services continuing to fall as clients become better equipped to do their own gene research.

Mac speculated that Incyte may unveil a drug-development strategy in a business meeting slated for the first quarter of 2002. Such a strategy might include hiring additional drug company veterans or acquisitions of small drug firms if and when Incyte`s depressed share price bounces back, the analyst added.

Incyte last month announced plans to restructure, including a 36 percent reduction in its 1,100-person work force. The company, which reported a third-quarter net loss of $17.8 million, said it planned to record a restructuring charge of at least $80 million in the fourth quarter.

Mac forecast that Incyte would report revenues in 2001 of $218 million, or a loss of 87 cents per diluted share. For 2002, he is predicting revenues of $200 million, with a loss of 77 cents per share.


Soweit sogut, es soll nun wieder in die richtige Richtung weitergehen !!

V.Mac

[V.Mac]

Wir werden am nächsten Handelstag in Deutschland noch mal steigende Kurse sehen !

In den USA war Schluß auf Tageshoch.

Warum ? Darum !

Incyte hat wohl die Patentstreitigkeiten mit Affymetrix beilgelegt.


Affymetrix and Incyte Genomics Settle All Patent Infringement Litigation

12/21/2001 4:05:00 PM
PALO ALTO, Calif. and SANTA CLARA, Calif., Dec 21, 2001 /PRNewswire via COMTEX/ -- Incyte Genomics, Inc. (INCY) , the leading genomics information company and Affymetrix, Inc., (AFFX) the leader in creating breakthrough tools for the genomic revolution, today announced a comprehensive settlement of all existing infringement litigation between the two companies. The first lawsuit involved several of Affymetrix microarray-related patents (U.S. Patent Nos. 5,445,934, 5,744305, 5,800,992, 5,871,928, 6,040,193). The second lawsuit involved Incyte`s RNA amplification patents (U.S. Patent Nos. 5,716,785, 5,891,636). The companies have agreed to cross-licenses under their respective intellectual property portfolios. Financial terms were not disclosed. Affymetrix and Incyte also are investigating possible future commercial agreements between the companies.

V.Mac

[V.Mac]

das letzte halbe Jahr lief auch für INCYTE nicht unbedingt optimal. Im Kurs gehts immer noch ein Stückchen tiefer, um dann mal wieder 10% zuzulegen. Aber zwei, drei Wochen später gehts wieder tiefer runter. Zur Zeit sind wir gerade noch um rund 7 Euro.

Wer weiss, wo dass noch hinführt ?!?!?

V.Mac

[V.Mac]

Heute ein schönes Plus nach dem schon weiter oben beschriebenen Kursverlusten. Warum geht es heute immerhin 20 % nuff ? Ich weis es nicht.

Kann natürlich so weitergehen.

V.Mac

[eser]

immer so

[V.Mac]

so ist die Welt.
In einer guten Woche von knapp 5 USD auf immerhin gut unter 3 USD zurückgefallen. Warum ? Nur weil ein neues Mitglied im Vorstand erscheint ?


Jason Rubin Joins Incyte Genomics as Executive Vice President of Corporate Affairs
WEDNESDAY, OCTOBER 09, 2002 7:01 AM - BusinessWire

PALO ALTO, Calif., Oct 9, 2002 (BUSINESS WIRE) -- Incyte Genomics, Inc. (INCY) announced today that Jason Rubin, 44, has joined the company as executive vice president of corporate affairs, a new position. Mr. Rubin is responsible for leading Incyte`s investor and public relations, employee and marketing communications, Internet communications, public policy and community affairs activities. Rubin is based at the company`s drug discovery facility in Newark, Del., and reports to chief executive officer Paul Friedman, M.D.

Before establishing his own communications consulting firm in 1999, Mr. Rubin was vice president of corporate communications at Centocor, Inc., Cephalon, Inc. and Immunex Corporation. Previously, he served as director of the biotechnology practice at Hill and Knowlton Public Affairs in Washington, D.C.

"We welcome Jason`s insights, counsel and guidance in communicating our progress as we expand our drug discovery efforts, continue our genomic database development programs and work to build shareholder value," Friedman said.

Mr. Rubin holds a master of science degree in management from M.I.T.`s Sloan School of Management and a bachelor of arts degree in geology from Middlebury College. He is a member of the National Investor Relations Institute and a frequent speaker on communications practices in the biotechnology industry.

Incyte Genomics, Inc., has the largest commercial portfolio of issued United States patents covering human, full-length genes and the proteins they encode. Incyte is leveraging its leading intellectual property and genomic information position to be a leader in discovering and developing therapeutic small molecules, secreted proteins and antibodies. In addition, Incyte has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and licenses pharmaceutically relevant intellectual property. These offerings facilitate pharmaceutical and biotechnology researchers in their drug discovery and development; including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease.


V.Mac